Company intelligence / Profile preview

Biowink GmbH

Ownership: Private
Development stage: Commercial

Overview

The company’s flagship product—the Clue app—has over 10 million active users in more than 190 countries. It provides science-based menstrual and fertility tracking with high accuracy ratings from medical journals. The company collaborates with leading academic institutions to advance research in female and reproductive health. Recent partnerships include studies on heavy menstrual bleeding with the Gates Foundation and integration of biometrics from ŌURA rings for enhanced user insights.

Therapeutic areas: Men's HealthWomen's Health
Modalities: Non-pharmacological therapy (digital health app)
Industry: Digital Health Medical Devices

Partnerships

Bill & Melinda Gates Foundation (study on heavy menstrual bleeding)Academic partners including Kinsey Institute, Stanford University, Columbia University, University of Oxford (research collaborations)

Beyond the preview

Go deeper on Biowink GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biowink GmbH.

Explore the full profile